An overview of methamphetamine-induced psychotic syndromes

Addictive Disorders and their Treatment

Volumn 7, Issue 3, 2008, Pages 143-156

  Zorick, Todd S ^a   Rad, David ^b   Rim, Christine ^b   Tsuang, John ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Methamphetamine; Psychosis; Review; Treatment

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DROPERIDOL; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; METHAMPHETAMINE; NEUROLEPTIC AGENT;

ABSTINENCE; ABUSE; ACUTE TOXICITY; ADRENERGIC SYSTEM; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; EPIDEMIC; EUPHORIA; HALLUCINATION; HUMAN; INTOXICATION; METHAMPHETAMINE INDUCED PSYCHOSIS; NONHUMAN; PARANOID PSYCHOSIS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDATION; THOUGHT DISORDER; UNITED STATES;

EID: 67649970228     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/ADT.0b013e318066d5e0     Document Type: Review

References (79)

1. Nordahl TE, SaloR,LeamonM.Neuropsychological effects of chronic methamphetamine use on neuro-transmitters and cognition: a review. J Neuropsy-chiatry Clin Neurosci. 2003;15:317-325.
2. National Institute on Drug Abuse. Methampheta-mine abuse and addiction [Research Reportseries]. 1998. http://165.112. Available at 78.61/ ResearchReports/Methamph/methamph4.html.
3. Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addict Dis. 2002;21:21-34.
4. Rawson R, Huber A, Brethen P, et al. Methamphe-tamine and cocaine users: differences in characteristics and treatment retention. J Psychoactive Drugs. 2000;32:233-238.
5. Suwaki H. Methamphetamine abuse in Japan: its history and the current situation. In: Klee H, ed. Amphetamine Misuse: International Perspectives on Current Trends. England: Harwood Academic; 1997:199-214.
6. Suwaki H. Methamphetamine abuse in Japan. NIDA Res Monogr. 1991;115:84-98.
7. Anglin MD, Burke C, Perrochet B, et al. History of the methamphetamine problem. J Psychoactive Drugs. 2000;32:137-141.
8. Greberman SB, Wada K. Social and legal factors related to drug abuse in the United States and Japan. Public Health Rep. 1994;109:731-737.
9. Miller MA. History and epidemiology of metham-phetamine abuse in the United States. In: Klee H, ed. Amphetamine Misuse: International Perspectives on Current Trends. England: Harwood Academic; 1997:113-134.
10. Morgan P, Beck JE. The legacy and the paradox: hidden contexts of methamphetamine use in the United States. In: Klee H, ed. Amphetamine Misuse: International Perspectives on Current Trends. Reading, England: Harwood Academic; 1997: 135-162.
11. Meredith CW, Jaffe C, Ang-Lee K, et al. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry. 2005;13:141-154.
12. Ely R, McGrath D. Lithium-ammonia reduction of ephedrine to methamphetamine: an unusual clandestine synthesis. J Forensic Sci. 1990;35: 720-723.
13. National Drug Intelligence Center. Methampheta-mine Drug Threat Assessment. March 2005. Available at www.usdoj.gov/ndic. Product No. 2005-Q0317-009.
14. National Drug Intelligence Center. Methampheta-mine. In: National Drug Threat Assessment 2003. Available at http://www.usdoj.gov/ndic/pubs3/ 3300/meth.htm.
15. Karch S. The problem of methamphetamine toxi-city. West J Med. 1999;170:232.
16. Gorelick DA, Cornish JL. The pharmacology of cocaine, amphetamines, and other stimulants. In: Graham A, Schultz T, Mayo-Smith M, et al, eds. Principles of Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine; 2003:157-190.
17. Cho AK, Melega WP, Kuczenski R, et al. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse. 2001;39: 161-166.
18. Zweben JE, Cohen JB, Christian D, et al. Metham-phetamine Treatment Project. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13:181-190.
19. Yu Q, Larson DF, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci. 2003; 73:129-140.
20. Kramer JC, Fischman VS, Littlefield CD. Amphetamine abuse. Pattern and effects of high doses taken intravenously. JAMA. 1967;201:305-309.
21. King GR, Ellinwood EH. Amphetamines and other stimulants. In: Lowinson JH, Ruiz P, Millman RB, et al, eds. Substance Abuse: A Comprehensive Textbook. Baltimore, MD: Williams & Wilkins; 1997:207-222.
22. Newton TF, Kalechstein AD, Duran S, et al. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict. 2004;13:248-255.
23. Seiden LS, Ricaurte GA. Neurotoxicity of metham-phetamine and related drugs. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987:359-366.
24. Ellinwood EH, King G, Lee TH. Chronic Amphetamine Use and Abuse. In Neuropsychopharmacol-ogy: The Fifth Generation of Progress: The American College of Neuropsychopharmacology 2000. Available at http://www.acnp.org/g4/ GN401000166/Default.htm
25. Cadet JL, Jayanthi S, Deng X. Speed kills: cellular and molecular bases of methamphetamine-in-duced nerve terminal degeneration and neuronal apoptosis. FASEB J. 2003;17:1775-1788.
26. Miyazaki I, Asanuma M, Diaz-Corrales FJ, et al. Methamphetamine-induced dopaminergic neuro-toxicity is regulated by quinone-formation-related molecules. FASEB J. 2006;20:571-573.
27. Utena H. Behavioral aberrations in methampheta-mine-intoxicated animals and chemical correlates in the brain. Prog Brain Res. 1966;21B:192-207.
28. Yui K, Ikemoto S, Ishiguro T, et al. Studies of amphetamine or methamphetamine psychosis in Japan. Ann NY Acad Sci. 2000;914:1-12.
29. Cadet JL, Jayanthi S, Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Neurotox Res. 2005;8:199-206.
30. Sekine Y, Iyo M, Ouchi Y, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001;158:1206-1214.
31. Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphe-tamine-related psychiatric symptoms. Am J Psychiatry. 2003;160:1699-1701.
32. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21:9414-9418.
33. Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methampheta-mine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry. 2001; 158:2015-2021.
34. Wang GJ, Volkow ND, Chang L, et al. Partial recoveryof brain metabolismin methamphetamine abusers after protracted abstinence. Am J Psychiatry. 2004;161:242-248.
35. Sekine Y, Minabe Y, Kawai M, et al. Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology. 2002;27:453-461.
36. Sekine Y, Ouchi Y, Takei N, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006;63:90-100.
37. Buffenstein A, Heaster J, Ko P. Chronic psychotic illness from methamphetamine. Am J Psychiatry. 1999;156:662.
38. Iyo M, Namba H, Yanagisawa M, et al. Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21:789-796.
39. Iyo M, Sekine Y, Mori N. Neuromechanism of developing methamphetamine psychosis: a neuro-imaging study. Ann N Y Acad Sci. 2004;1025: 288-295.
40. Thompson PM, Hayashi KM, Simon SL, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004; 24:6028-6036.
41. London ED, Simon SL, Berman SM, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methampheta-mine abusers. Arch Gen Psychiatry. 2004;61:73-84.
42. London ED, Berman SM, Voytek B, et al. Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry. 2005;58:770-778.
43. Kalechstein AD, Newton TF, Green M. Methamphe-tamine dependence is associated with neurocogni-tive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci. 2003;15:215-220.
44. Monterosso JR, Aron AR, Cordova X, et al. Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend. 2005;79:273-277.
45. Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict. 2004;13:461-470.
46. Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subs Abuse and Treatment. 2002;23:145-150.
47. Alberston TE, Derlet RW, Van Hoozen BE. Metham-phetamine and the expanding complications of amphetamines. West J Med. 1999;170:214-219.
48. Thirthalli J, Benegal V. Psychosis among substance users. Curr Opin Psychiatry. 2006;19:239-245.
49. Smith DE, Fishcer CM. An analysis of 310 cases of acute high-dose methamphetamine toxicity in Haight-Ashbury. Clin Toxicol. 1970;3:117-124.
50. Connell PH. Amphetamine Psychosis. New York, NY: Oxford University Press; 1958.
51. Dealy J, Pichot P, Lempérière T, et al. Psychoses amphétaminiques. Ann Med Psychol. 1954;112: 51-57.
52. Shimazono Y, Matsushima E. Behavioral and neu-roimaging studies on schizophrenia in Japan. Ann NY Acad Sci. 1995;49:3-11.
53. Yui K, Goto K, Ikemoto S, et al. Methamphetamine psychosis: spontaneous recurrence of paranoid-hallucinatory states and monoamine neurotrans-mitter function. J Clin Psychopharm. 1997;17: 34-43.
54. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann NY Acad Sci. 2004;1025:279-287.
55. Fujii D. Risk factors for treatment-resistive metham-phetamine psychosis. J Neuropsychiatry Clin Neu-rosci. 2002;14:239-240.
56. Chen CK, Lin SK, Sham PC, et al. Pre-morbid characteristics and co-morbidity of methampheta-mine users with and without psychosis. Psychol Med. 2003;33:1407-1414.
57. Chen CK, Lin SK, Sham PC, et al. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Gen. 2005;136B:87-91.
58. Caton CLM, Drake RE, Hasin DS, et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry. 2005;62: 137-145.
59. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann NY Acad Sci. 1992;654:160-170.
60. Ujike H, Harano M, Inada T, et al. Nine- or fewer repeat alleles in VNTR polymorphism of the dopa-mine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharma-cogenomics J. 2003;3:242-247.
61. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psy-chopharmacology (Berl). 1987;91:415-433.
62. Yui K, Goto K, Ikemoto S, et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitiza-tion. Mol Psychiatry. 1999;4:512-523.
63. Sadock BJ, Sadock VA, Kaplan HI. Kaplan and Sadock's Comprehensive Textbook of Psychiatry (Comprehensive Textbook of Psychiatry). 8th ed. New York University, New York City, NY: Lippincott Williams & Wilkins; 2004.
64. Ellinwood EH Jr. Amphetamine psychosis: I description of the individual and process. J Nervous and Mental Disease. 1967;144:273-283.
65. Kalant OJ. The Amphetamines-Toxicity and Addiction. Toronto: University of Toronto Press; 1966.
66. Tomiyama G. Chronic schizophrenia-like states in methamphetamine psychosis. Jpn J Psychiatr Neu-rol. 1990;44:531-539.
67. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000;9:28-37.
68. Srisurapanont M, Ali R, Marsden J, et al. Psychotic symptoms in methamphetamine psychotic in-patients. Inter J Neuropsychopharm. 2003; 6:347-352.
69. Yeh HS, Lee YC, Sun HJ, et al. Six months follow-up of patients with methamphetamine psychosis. Zhonghua Yi Xue Za Zhi (Taipei). 2001;64: 388-394.
70. Hillard JR. Emergency treatment of acute psychosis. J Clin Psychiatry. 1998;59(suppl 1):57-60; discussion 61.
71. Richards JR, Derlet RW, Duncan DR. Methamphe-tamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med. 1997;4:130-135.
72. Shaner A, Roberts LJ, Eckman TA, et al. Sources of diagnostic uncertainty for chronically psychotic cocaine abusers. Psychiatr Serv. 1998;49:684-690.
73. Misra L, Kofoed L. Risperidone treatment of methamphetamine psychosis. Am J Psychiatry. 1997;154:1170.
74. Misra LK, Kofoed L, Oesterheld JR, et al. Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol. 2000;20:393-394.
75. Dore G, Sweeting M. Drug-induced psychosis associated with crystalline methamphetamine. Austra-las Psychiatry. 2006;14:86-89.
76. Iyo M, Sekine Y, Matsunaga T, et al. Methampheta-mine-associated obsessional symptoms and effective risperidone treatment: a case report. J Clin Psychiatry. 1999;60:337-338.
77. Guilarte TR. Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology. 2001;22: 725-731.
78. Tsuang JW, Fong TW, Ho AP. Dual diagnosis and treatment compliance. Psychiatr Serv. 2003; 54:576.
79. Tsuang J, Fong TW. Treatment of patients with schizophrenia and substance abuse disorders. Curr Pharm Des. 2004;10:2249-2261.